Barinthus

New partnership aims to advance vaccine against MERS coronavirus

Retrieved on: 
星期四, 十二月 21, 2023
Epidemic, Partnership, Immune system, University of Oxford, Infection, PRIME, EMA, Urinary tract infection, Barinthus, WHO, Oxford–AstraZeneca COVID-19 vaccine, Vaccine, MERS, MERS-related coronavirus, CEPI, Vaccination, Coalition, Clinical trial, Cancer, University, ChAdOx1, COVID-19, European Medicines Agency, Policy, Public, Coronavirus, Phase II, Medicine, Public health, Autoimmunity, Pharmaceutical industry

“We had a head-start in our development of the Oxford/AstraZeneca COVID-19 vaccine, thanks to the many years already spent researching a vaccine for another coronavirus, MERS.

Key Points: 
  • “We had a head-start in our development of the Oxford/AstraZeneca COVID-19 vaccine, thanks to the many years already spent researching a vaccine for another coronavirus, MERS.
  • “There is an active need for a MERS vaccine for at-risk populations and travellers in the Middle East.
  • MERS is a severe respiratory infection caused by MERS-CoV, a coronavirus that was first identified in 2012 in Saudi Arabia.
  • The vaccine will be made available to low- and middle-income countries at a price no higher than the cost of manufacturing plus 10 percent.

Vaccitech Renames as Barinthus Biotherapeutics to Highlight Strategic Evolution into a T Cell Immunotherapy Company Targeting Chronic Infectious Diseases, Autoimmunity, and Cancer

Retrieved on: 
星期一, 十一月 6, 2023
Avalon, Modified vaccinia Ankara, Autoimmunity, American Association for Cancer Research, Hepatology, Vaccine, Liver, Immunogenicity, LDN, PD-1, University, CHB, Research, Barinthus, Immune system, COVID-19, Efficacy, MVA, Hepatitis, Repeat, Hepatitis B, Infection, Cancer, HBsAg, Patient, Asian Liver Center, HBV, AASLD, Pharmaceutical industry, Oxford–AstraZeneca COVID-19 vaccine, Safety

The company also announced today that it has changed its name to Barinthus Biotherapeutics plc to represent the evolution and expansion of its focus beyond vaccines. The company expects to begin trading under its new name and ticker (Nasdaq: BRNS) effective as of November 7, 2023. As part of the rebranding, the company has also updated its website -- learn more at www.barinthusbio.com.

Key Points: 
  • The company also announced today that it has changed its name to Barinthus Biotherapeutics plc to represent the evolution and expansion of its focus beyond vaccines.
  • The company expects to begin trading under its new name and ticker (Nasdaq: BRNS) effective as of November 7, 2023.
  • As part of the rebranding, the company has also updated its website -- learn more at www.barinthusbio.com .
  • “Today the company is focused on the development of novel T cell immunotherapeutic candidates, which evolved out of that initial vaccine research.